Sihao Liu

age ~40

from Carlsbad, CA

Get Report
Related to:
Connected to:

Sihao Liu Phones & Addresses

  • Carlsbad, CA
  • 3052 Rue Dorleans UNIT 117, San Diego, CA 92110
  • La Jolla, CA
  • Jamaica Plain, MA
  • Cambridge, MA
  • Ithaca, NY
  • 5 Cowperthwaite St, Cambridge, MA 02138

Work

  • Company:
    Ionis pharmaceuticals, inc.
    Apr 2019 to Jul 2020
  • Position:
    Senior scientist

Education

  • School / High School:
    Harvard Medical School
    2007 to 2012
  • Specialities:
    Human Biology and Translational Medicine

Skills

Molecular Cloning • Molecular Biology • Cell Biology • Biochemistry • Animal Models • Cell Culture • In Vivo Assessment of Glucose Homeostasi... • In Vivo Assessment of Lipid Homeostasis ... • High Level Statistical Analysis of Micro... • Basic Fluency In R Statistical Computing... • Primary Hepatocytes and Adipocytes Isola... • Analysis of Gene Expression Using Real T... • Use of Crispr Cas9 To Generate Knockout/... • Rnaseq • Translating Ribosome Affinity Purification • Stereotaxic Injection In Rodents • Flow Cytometry • Data Analysis • Genetics • Western Blotting • Real Time Polymerase Chain Reaction • Fluorescence Microscopy • Mammalian Display Technology • Error Prone Pcr • Atac Seq • Gene Editing • Gene Expression • Immunofluorescence • Immunoprecipitation • Crispr • Lentivirus • Adenovirus • Chromatin Immunoprecipitation • Rnai • Rna Isolation • Confocal Microscopy • High Throughput Screening • Site Directed Mutagenesis • Directed Evolution • Display Technology • In Vivo

Languages

Mandarin • English

Industries

Biotechnology

Resumes

Sihao Liu Photo 1

Co-Founder

view source
Location:
San Diego, CA
Industry:
Biotechnology
Work:
Ionis Pharmaceuticals, Inc. Apr 2019 - Jul 2020
Senior Scientist
Salk Institute For Biological Studies Sep 2013 - Apr 2019
Postdoctoral Fellow
Harvard School of Public Health Feb 2013 - Aug 2013
Postdoctoral Fellow
Harvard University Aug 2007 - Dec 2012
Graduate Researcher
Cornell University Aug 2006 - May 2007
Undergraduate Honor Thesis
Education:
Harvard Medical School 2007 - 2012
Harvard University School of Public Health 2007 - 2012
PhD, Physiology and Molecular Biology Cornell University 2005 - 2007
B.S, Food Science China Agricultural University 2003 - 2007
B.S, Biological Science
Skills:
Molecular Cloning
Molecular Biology
Cell Biology
Biochemistry
Animal Models
Cell Culture
In Vivo Assessment of Glucose Homeostasis In Rodents
In Vivo Assessment of Lipid Homeostasis In Rodents
High Level Statistical Analysis of Microarray and Metabolomics
Basic Fluency In R Statistical Computing Environment
Primary Hepatocytes and Adipocytes Isolation and Culture
Analysis of Gene Expression Using Real Time Pcr
Use of Crispr Cas9 To Generate Knockout/Knockin Cells
Rnaseq
Translating Ribosome Affinity Purification
Stereotaxic Injection In Rodents
Flow Cytometry
Data Analysis
Genetics
Western Blotting
Real Time Polymerase Chain Reaction
Fluorescence Microscopy
Mammalian Display Technology
Error Prone Pcr
Atac Seq
Gene Editing
Gene Expression
Immunofluorescence
Immunoprecipitation
Crispr
Lentivirus
Adenovirus
Chromatin Immunoprecipitation
Rnai
Rna Isolation
Confocal Microscopy
High Throughput Screening
Site Directed Mutagenesis
Directed Evolution
Display Technology
In Vivo
Languages:
Mandarin
English

Us Patents

  • Fibroblast Growth Factor 1 (Fgf1) Mutant Proteins That Selectively Activate Fgfr1B To Reduce Blood Glucose

    view source
  • US Patent:
    20210032303, Feb 4, 2021
  • Filed:
    Jul 15, 2020
  • Appl. No.:
    16/929342
  • Inventors:
    - La Jolla CA, US
    Michael Downes - San Diego CA, US
    Annette Atkins - San Diego CA, US
    Sihao Liu - San Diego CA, US
    Ruth T. Yu - La Jolla CA, US
  • Assignee:
    Salk Institute for Biological Studies - La Jolla CA
  • International Classification:
    C07K 14/50
    A61P 3/10
  • Abstract:
    The present disclosure provides FGF1 mutant proteins, which selectively bind to/activate FGFR1b. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. Methods of using the disclosed FGF1 mutants to reduce blood glucose in a mammal and treat a metabolic disorder are provided.

  • Use Of Fibroblast Growth Factor 1 (Fgf1)-Vagus Nerve Targeting Chimeric Proteins To Treat Hyperglycemia

    view source
  • US Patent:
    20190276510, Sep 12, 2019
  • Filed:
    May 22, 2019
  • Appl. No.:
    16/419929
  • Inventors:
    - La Jolla CA, US
    Michael Downes - San Diego CA, US
    Annette Atkins - San Diego CA, US
    Ruth T. Yu - La Jolla CA, US
    Sihao Liu - San Diego CA, US
  • Assignee:
    Salk Institute for Biological Studies - La Jolla CA
  • International Classification:
    C07K 14/50
    A61K 38/26
    A61K 47/64
    A61P 3/10
    A61P 3/04
  • Abstract:
    The present disclosure provides FGF1 mutant proteins, which include an N-terminal deletion, point mutation(s), or combinations thereof, as well as FGF1-vagus targeting chimeric proteins which include an FGF1 portion (e.g., native FGF1 or mutant FGF1) and a portion that targets the chimera to the vagus nerve (e.g., GLP or exendin-4). Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. The disclosed FGF1 mutants and FGF1-vagus targeting chimeric proteins can reduce blood glucose in a mammal, and in some examples are used to treat a metabolic disorder.

  • Fibroblast Growth Factor (Fgf) 1 Proteins With Glucose Lowering Ability And Reduced Mitogenicity

    view source
  • US Patent:
    20190151416, May 23, 2019
  • Filed:
    Jan 18, 2019
  • Appl. No.:
    16/252292
  • Inventors:
    - La Jolla CA, US
    Michael Downes - La Jolla CA, US
    Annette Atkins - La Jolla CA, US
    Ruth T. Yu - La Jolla CA, US
    Sihao Liu - La Jolla CA, US
  • Assignee:
    Salk Institute for Biological Studies - La Jolla CA
  • International Classification:
    A61K 38/18
    C07K 14/50
    A61P 3/10
    C12N 15/62
    A61P 1/16
    A61K 31/4439
  • Abstract:
    The present disclosure provides FGF1 mutant proteins, which include an N-terminal deletion, point mutation(s), or combinations thereof. In some examples, the mutant FGF1 proteins have reduced mitogenic activity. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. The disclosed FGF1 mutants can reduce blood glucose in a mammal, and in some examples are used to treat a metabolic disorder.

Googleplus

Sihao Liu Photo 2

Sihao Liu

Lived:
Boston,MA
Education:
Harvard University, China Agricultural University, Cornell University
About:
Tech Hobbist
Sihao Liu Photo 3

Sihao Liu

Get Report for Sihao Liu from Carlsbad, CA, age ~40
Control profile